Archive
This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Ally Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Cheuk Man Tsang
- Chris Barber
- Crina Heghes
- Daragh Connolly
- Dave Yeo
- David Ponting
- Emma Scrafton
- Fabrizio Campo
- Fernanda Waechter
- Grace Kocks
- Hazel Gardiner
- James McManus
- Jess Tidmarsh
- Jessica Magallanes-Castaneda
- Josh Cosby
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Martyn Chilton
- Michael Burns
- Nik Marchetti
- Oana Leonte
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rachel Hemingway
- Raeesah Saddiq
- Rob Foster
- Sara Atkinson
- Scott McDonald
- Susanne Stalford
Filter by Product
The benefits of joining the Complex Nitrosamines consortium
Read what one of our Complex Nitrosamines Data Sharing Initiative members, Graham Smith, Oncology Chemical Toxicology Lead at AstraZeneca, has to say about being involved in this growing consortium!
10 October 2022
Nitrites in Excipients Data Sharing Consortium: Supporting Nitrosamine Risk Assessment
Nitrite analysis of excipients is a new and analytically challenging area, with many organisations working quickly to determine the best practice and techniques to use.
The Nitrites in Excipients data sharing consortium was established in September 2020 and is part of Lhasa Limited's effort to support the global challenge of nitrosamine risk assessment.
22 February 2022
20 tips for nitrosamine impurity assessment
Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
The top 5 benefits of data sharing with Vitic [an infographic]
Lhasa Limited has been an advocate of data sharing for many years. In this piece, we explore the top 5 benefits of data sharing with Vitic.
08 April 2021
Working together to address the potential presence of nitrosamine impurities in medications
Lhasa Limited, in collaboration with Leadscope, Inc., are leading a working group of pharmaceutical toxicologists and consultants investigating the carcinogenic potency and structure-activity relationships of N-nitrosamines.
25 January 2021
Lhasa Limited supports the global challenge of nitrosamine impurity assessment
The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.
13 July 2020
The Importance of Pre-competitive Collaborations
Throughout the history of science, progression has relied upon the generation of new knowledge and then building on that knowledge in order to gain even greater insight. In order to progress, this knowledge needs to be shared as widely as possible.
26 June 2020
Lhasa Limited supports an international initiative in the fight against COVID-19
Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
25 June 2020